Lenacapavir with Fostemsavir in a Multidrug-Resistant HIV-Infected Hemodialysis Patient
We report a hemodialysis MDR HIV-infected patient switched to fostemsavir with lenacapavir plus lamivudine for more than a year. She maintained a suppressed viral replication and did not present any clinical or biological drug-related side effects. The combination of lenacapavir plus fostemsavir loo...
Saved in:
| Main Authors: | Ferdinand Bigirimana, Sigi Van den Wijngaert, Christelle Fosso, Karolien Stoffels, Charlotte Martin, Evelyne Maillart, Philippe Clevenbergh |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-01-01
|
| Series: | Case Reports in Infectious Diseases |
| Online Access: | http://dx.doi.org/10.1155/2023/8865265 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Investigation of Natural Resistance to Fostemsavir and Lenacapavir in Naïve Primary Infections by Ultra-Deep Sequencing of near Full-Length HIV-1 Genomes
by: Elisabetta Lazzari, et al.
Published: (2025-04-01) -
Performance of Xpert MTB/RIF Ultra for diagnosis of pulmonary and extra-pulmonary tuberculosis, one year of use in a multi-centric hospital laboratory in Brussels, Belgium.
by: Leila Mekkaoui, et al.
Published: (2021-01-01) -
Sunlenca® (Lenacapavir): A first-in-class, long-acting HIV-1 capsid inhibitor for treating highly multidrug-resistant HIV-1 infection
by: Chunhua Ma, et al.
Published: (2024-12-01) -
Impact of HIV-1 capsid polymorphisms on viral infectivity and susceptibility to lenacapavir
by: Derek Hansen, et al.
Published: (2025-05-01) -
The primary mechanism for highly potent inhibition of HIV-1 maturation by lenacapavir.
by: Szu-Wei Huang, et al.
Published: (2025-01-01)